Potential of tetracyclines to modify cartilage breakdown in osteoarthritis

Current Opinion in Rheumatology

Volumn 8, Issue 3, 1996, Pages 238-247

  Ryan, Maria E ^a   Greenwald, Robert A ^b   Golub, Lorne M ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b LONG ISLAND JEWISH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE; TETRACYCLINE; TETRACYCLINE DERIVATIVE;

COLLAGEN DEGRADATION; DISEASE SEVERITY; DRUG FORMULATION; DRUG USE; EXTRACELLULAR MATRIX; HUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0030015151     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199605000-00013     Document Type: Review

References (76)

1. Creamer P, Dieppe P: Novel drug treatment strategies for osteoarthritis. J Rheumatol 1993, 20:1461-1464.
2. Hodgson J: Remodeling MMPIs. Biotechnology 1995, 13:554-557.
3. Birkedal-Hansen H, Moore W, Bodden M, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Engler JA: Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993, 4:197-250.
4. Ryan ME, Ramamurthy NS, Golub LM: Matrix metalloproteinases and their inhibition in periodontal treatment. Curr Opin Periodont 1996, 3:85-96. This recent review presents all current work pertaining to the inhibition of MMPs as a therapeutic modality for periodontal disease. The structure, activation, and specificity of the family of MMPs and the regulation of their expression are discussed. The relationship between MMP activity and periodontal pathogenesis is summarized, including the sources of MMP production regulated by cytokines and growth factors and the temporal relationship of gingival MMP activity and alveolar bone loss. A section is dedicated to both endogenous and synthetic inhibitors. The multiple mechanisms of MMP inhibition by tetracycline analogues are detailed. Both animal models and human studies relevant to the proposed role of inhibitors in the treatment of periodontitis are presented. The numerous medical implications of the nonantimicrobial anti-MMP properties of tetracyclines are listed.
5. Baramova E, Foidart J-M: Matrix metalloproteinase family. Cell Biol Int 1995, 19:239-242.
6. Martel-Pelletier J, McCollum R, Fujimoto N, Obata K'I, Cloutier J-M, Pelletier J-P: Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis. Lab Invest 1994, 70:807-815.
7. Cawston TE, Curry V, Ramsey S, Clark IM, Kyle VA, Adebajo A, Silverman B, Daymond T, Hazleman BL: The levels of collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), collagenase-TIMP-1 complexes and glycosaminoglycan (GAG) in sequential samples of synovial fluid aspirated from patients with osteoarthritis. Clin Exp Rheumatol 1995, 13:431-437.
8. Golub L, Evans R, McNamara T, Lee H, Ramamurthy N: A non-antimicrobial tetracycline inhibits gingival matrix metalloproteinases and bone loss in Porphyromonas gingivalis-induced periodontitis in rats. Ann N Y Acad Sci 1994, 732:96-111. Convincing evidence that tetracycline, by a nonantimicrobial property, inhibits several MMPs and also prevents alveolar bone loss in a P. gingivalis-induced rat model of adult periodontitis; also a detailed discussion of the multiple mechanisms of tetracycline inhibition.
9. Brandt KD: Toward pharmacologic modification of joint damage in osteoarthritis. Ann Intern Med 1995, 122:874-875.
10. Gross J, Lapiere CM: Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci U S A 1962, 48:1014-1020.
11. Woessner J Jr: The family of matrix metalloproteinases. Ann N Y Acad Sci 1994, 732:11-21. This extensive review describes the origins of MMPs and the criteria that define these enzymes as members of the family of MMPs. The roles that MMPs play in mammalian function and the biologic roles of the various domains of their molecular structure are addressed. The regulation of MMPs and the interrelationships between extracellular matrix and MMPs are also presented.
12. Ries C, Petrides P: Cytokine regulation of MMP activity and its regulatory dysfunction in disease. Biol Chem 1995, 376:345-355.
13. Lovejoy B, Cleasby A, Hassell A, Longely K, Luther M, Weigl D, McGeehan G, McElroy AB, Drewry D, Lambert MH, Jordan SR: Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor. Science 1994, 263:375-377.
14. Williams DH, Murray EJ: Specific amino acid substitutions in human collagenase cause decreased autoproteolysis and reveal a requirement for a second zinc for catalytic activity. FEBS Lett 1994, 354:267-270.
15. Goldberg QI, Strongin A, Collier IE, Genrich LT, Marmer BL: Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem 1992, 267:4583-4591.
16. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M: A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994, 370:61-65.
17. Murphy G, Docherty AJP, Hembry RM, Reynolds JJ: Metalloproteinases and tissue damage. Br J Rheumatol 1995, 30:25-31.
18. Taraboletti G, Gaofalo A, Belotti D, Drudis T, Borsotti P, Scanziani E, Brown PD, Giavazzi R: Inhibition of angiogenesis and murine hemangioma growth by Batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 1995, 87:293-298.
19. Brown P: Matrix metalloproteinase inhibitors: a new class of anticancer drugs. Curr Opin Invest Drugs 1993, 2:617-624.
20. Harris ED, Welgus HG, Krane SM: Regulation of the mammalian collagenases. Collagen Rel Res 1984, 4:493-499.
21. Golub LM, Lee HM, Lehrer G, Nemiroff A, McNamara TF, Kaplan R, Ramamurthy NS: Minocycline reduces gingival collagenolytic activity during diabetes: preliminary observations and a proposed new mechanism of action. J Periodont Res 1983, 18:516-526.
22. Golub L, Wolff M, Lee H, McNamara TF, Ramamurthy NS, Zambon J, Cianco SG: Further evidence that tetracyclines inhibit collagenase activity in human crevicular fluid and from other mammalian sources. J Periodont Res 1985, 20:12-23.
23. Golub L, Ramamurthy N, McNamara T, Greenwald R, Rifkin B: Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med 1991, 2:297-322.
24. Golub L, Ciancio S, Ramamurthy N, Leung M, McNamara T: Low dose doxycycline therapy: effect on gingival and crevicular fluid collagenase activity in humans. J Periodont Res 1990, 25:321-330.
25. Crout RJ, Lee HM, Schroeder K, Crout H, Ramamurthy NS, Wiener M, Golub LM: The "cyclic" regimen of low-dose doxycycline for adult periodontitis: a preliminary study. J Periodontol 1996, 67:506-514.
26. Galardy R, Cassabonne M, Giese C, Gilbert J, Lapierre F, Lopez H, Schaeffer ME, Stack R, Sullivan M, Summers B, et al.: Low molecular weight inhibitors of corneal ulceration. Ann N Y Acad Sci 1994, 732:315-323.
27. Borkakoti N, Winkler F, Williams D, D'Arcy A, Broadhurst MJ, Brown PA, Johnson WH, Murray EJ: Structure of the catalytic domain of human fibroblast collagenase complexed with an inhibitor. Struct Biol 1994, 1:106-110.
28. Hill P, Docherty A, Bottomley K, O'Connell JP, Murphy JR, Reynolds JJ, Meikle MC: Inhibition of bone resorption in vitro by selective inhibitors of gelatinase and collagenase. Biochem J 1995, 388:167-175.
29. Greenwald R: Treatment of destructive arthritic disorders with MMP inhibitors: potential role of tetracyclines. Ann N Y Acad Sci 1994, 732:181-198. A review of MMP activity in both rheumatoid arthritis and osteoarthritis. MMP activity and the therapeutic use of MMP inhibitors in animal models are presented. Means of monitoring disease progression are proposed. Treatment of human arthritis with tetracyclines is discussed.
30. Dean D: Proteinase-mediated cartilage degradation in osteoarthritis. Semin Arthritis Rheum 1991, 20:2-11.
31. Carney S: Cartilage research, biochemical, histologic, and immunohistochemical markers in cartilage, and animal models of osteoarthritis. Curr Opin Rheumatol 1991, 3:669-675.
32. Burton-Wurster N, Todhunter R, Lust G: Animal models of osteoarthritis. In Joint Cartilage Degradation: Basic and Clinical Aspects. Edited by Woessner J, Howell D. New York: Marcel Dekker; 1993:347-384.
33. Zafarullah M, Pelletier J, Cloutier J, Marcel-Pelletier J: Elevated metalloproteinases and tissue inhibitor of metalloproteinase mRNA in human osteoarthritis synovia. J Rheumatol 1993, 20:693-697.
34. Hembry R, Bagga M, Reynolds J, Hamblen D: Immunolocalisation studies on six matrix metalloproteinases and their inhibitors, TIMP-1 and TIMP-2, in synovia from patients with osteo- and rheumatoid arthritis. Ann Rheum Dis 1995, 54:25-32.
35. Manicourt D-H, Fujimoto N, Obata K, Thonar EJ: Serum levels of collagenase, stromelysin-1 and TIMP-1. Arthritis Rheum 1994, 37:1774-1783.
36. Wernicke D, Seyfert C, Hinzmann B, Gromnica-Ihle E: Cloning of collagenase 3 from the synovial membrane and its expression in rheumatoid arthritis and osteoarthritis. J Rheumatol 1996, 23:590-595.
37. Shingu M, Nagai Y, Isayama T, Naono T, Nobunaga M, Nagai Y: The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clin Exp Immunol 1993, 94:145-149.
38. Mohtai M, Smith R, Schurman D, Tauji Y, Torti FM, Hutchinson NI, Stetler-Stevenson WG, Goldberg GI: Expression of 92kD type IV collagenase/gelatinase (gelatinase B) in osteoarthritic cartilage and its induction in normal human articular cartilage by IL-1. J Clin Invest 1993, 92:179-185.
39. Thompson RWT, Harvin H, Liao S, Callery MC: Doxycycline suppresses serum tumor necrosis factor-α (TNF-α) levels in lipopolysaccharide-challenged rats. Surg Infect Soc 1996, in press.
40. Gearing AJH, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL, et al.: Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature 1994, 370:555-557.
41. McGeehan GM, Becherer JD, Bast Jr RC, Boyer CM, Champion B, Connolly KM, Conway JG, Furdon P, Karp S, Kidao S, et al.: Regulation of tumor necrosis factor-α processing by a metalloproteinase inhibitor. Nature 1994, 370:558-561.
42. Nguyen Q, Murphy G, Hughes C, Mort JS, Roughley P: Matrix metalloproteinase cleaves at two distinct sites on human cartilage link protein. Biochem J 1993, 295:595-598.
43. Fosang AJ, Last K, Knauper V, Neame PJ, Murphy G, Hardingham TE, Tschesche H, Hamilton JA: Fibroblast and neutrophil collagenases cleave at two sites in the cartilage aggrecan interglobular domain. Biochem J 1993, 295:273-276.
44. Pokharna H, Monnier V, Boja B, Moskowitz R: Lysyl oxidase and Maillard reaction-mediated crosslinks in aging and osteoarthritic rabbit cartilage. J Orthop Res 1995, 13:13-21.
45. Vlassara H, Brownlee M, Manogue K, Dinarello C, Pasagian A: Cachectin/TNF and IL-1 induced by glucose modified proteins: role in normal tissue modeling. Science 1988, 240:1546-1548.
46. Scheller M, Zimmremann B, Bernimoulin J-P, Scholz P: Induction of metalloproteinase activity, cartilage matrix degradation and inhibition of endochondral mineralization in vitro by E. coli lipopolysaccharide is mediated by interleukin 1α. Cytokine 1995, 7:331-337.
47. Chowdhury M, Moak S, Rifkin B, Greenwald R: Effect of tetracyclines which have metalloproteinase inhibitory capacity on basal and heparin-stimulated bone resorption by chick osteoclasts. Agents Actions 1993, 40:124-128.
48. Rifkin B, Vernillo A, Golub L, Ramamurthy N: Modulation of bone resorption by tetracyclines. Ann N Y Acad Sci 1994, 732:165-180. This review covers the role of collagenase in bone resorption. It also provides an extensive discussion of the effects of tetracyclines on bone metabolism, particularly their inhibitory effects on several parameters of osteoclast function.
49. Ramamurthy NS, Vernillo AT, Lee HM, Golub LM, Rifkin BR: The effect of tetracycline on collagenase activity in UMR 106-01 rat osteoblastic osteosarcoma cells. Res Commun Chem Pathol Pharmacol 1990, 70:323-325.
50. Ramamurthy NS, Vernillo AT, Greenwald RA, Lee HM, Sorsa T, Golub LM, Rifkin BR: Reactive oxygen species activate and tetracyclines inhibit rat osteoblast collagenase. J Bone Miner Res 1993, 8:1247-1253.
51. Aimes R, Quigley J: Matrix metalloproteinase-2 is an interstitial collagenase. J Biol Chem 1995, 270:5872-5876.
52. Golub LM, McNamara TF, D'Angelo G, Greenwald RA, Ramamurthy NS: A non-antibacterial chemically-modified tetracycline inhibits mammalian collagenase activity. J Dent Res 1987, 66:1310-1314.
53. Ramamurthy N, Golub L, McNamara T, Vernillo A, Ausmann J, Rifkin B: A non-anticollagenase tetracyclines analog (CMT-5) inhibits oxidative activation of matrix metalloproteinases (MMPs) [abstract]. J Dent Res 1995, 74:207.
54. Cole A, Chubinskaya S, Luchene L, Chlebek K, Orth MW, Greenwald RA, Kuettner K, Schmid TM: Doxycycline disrupts chondrocyte differentiation and inhibits cartilage matrix degradation. Arthritis Rheum 1994, 37:1727-1734.
55. Cole AA, Yi X-W, Kuettner KE, Golub LM, Greenwald RA: The effect of chemically modified tetracyclines on cartilage degradation in chicken tibial explants. Trans Orthop Res Soc 1995, 20:337.
56. Steinmeyer J, Daufeldt S, Kalbhen DA: Pharmacologic influence on the activity of stromelysin from bovine articular cartilage. Ann N Y Acad Sci 1994, 732:482-483.
57. Yu L, Smith G, Hasty K, Brandt K: Doxycycline inhibits type XI collagenolytic activity of extracts from human osteoarthritic cartilage and of gelatinase. J Rheumatol 1991, 18:1450-1452.
58. Brandt K: Insights into the natural history of osteoarthritis provided by the cruciate-deficient dog. Ann N Y Acad Sci 1994, 732:199-205. The details of the model are discussed. The effects of antirheumatic drugs on articular cartilage and the relationship of synovitis to articular cartilage changes in osteoarthritis are described. The neurogenic acceleration of osteoarthritis and the involvement of periarticular muscle and subchondral bone in the etiopathogenesis of osteoarthritis are detailed. The modification of osteoarthritis by oral doxycycline therapy is discussed.
59. Smith G, Brandt K, Hasty K: Procollagenase is reduced to inactive fragments upon activation in the presence of doxycycline. Ann N Y Acad Sci 1994, 732:436-438.
60. Sorsa T, Ding Y, Salo T, Lauhio A, Teronen O, Ingman T, Ohtani H, Andoh N, Takeha S, Konttinen YJ: Effects of tetracyclines on neutrophil, gingival and salivary collagenases: a functional and Western blot assessment with special references to their cellular sources in periodontal diseases. Ann N Y Acad Sci 1994, 732:112-131.
61. Smith G, Hasty K: Structural basis for MMP-inhibition by doxycycline. Mol Biol Cell 1995, 6(suppl):173a.
62. Golub L, Suomalainen K, Sorsa T: Host modulation with tetracyclines and their chemically modified analogues. Curr Opin Dent 1992, 2:80-90.
63. Rifkin B, Vernillo A, Golub L: Blocking, periodontal disease progression by inhibiting tissue-destructive enzymes: a potential therapeutic role for tetracyclines and their chemically-modified analogs. J Periodont 1993, 64:819-827.
64. Ryan M, Ramamurthy N, Sorsa T, Ding Y, Golub L: Inhibition of periodontitis, as a complication of diabetes, by chemically modified tetracyclines. J Dent Res 1996, 75:371.
65. Ryan M, Ramamurthy N, Golub L: Six CMTs modulate MMPs and non-enzymatic glycosylation in diabetic rats [abstract]. J Dent Res 1995b, 74:138.
66. Chang K, Ramamurthy N, McNamara T, Evans RT, Klausen B, Murray PA, Golub LM: Tetracyclines inhibit Porphyromonas gingivalis-induced alveolar bone loss in rats by a non-antimicrobial mechanism. J Periodont Res 1994, 29:242-249.
67. Ramamurthy N, Golub L, Sorsa T, Salo T, Ding Y: Endotoxin induces MMP mediated bone loss in rat periodontium: inhibition of matrix metalloproteinases by CMTs. J Dent Res 1996, 75:105.
68. Greenwald R, Simonson B, Moak S, Ramamurthy N, Laskin R, Golub L: Inhibition of epiphyseal cartilage collagenase by tetracyclines in low phosphate rickets in rats. J Orthop Res 1988, 6:695-703.
69. Greenwald R, Golub L, Lavaites B, Ramamurthy NS, Gruber B, Laskin RS, McNamara TF: Minocycline inhibits rheumatoid synovial collagenase in vivo and in vitro. J Rheumatol 1987, 14:23-28.
70. Greenwald R, Moak S, Ramamurthy N, Golub L: Tetracyclines suppress metalloproteinase activity in adjuvant arthritis, and in combination with flurbiprofen, ameliorate bone damage. J Rheumatol 1992, 18:927-938.
71. Ramamurthy N, Greenwald R, Moak S, Sciubba J, Goren A, Turner G, Rifkin B, Golub L: CMT/tenidap treatment inhibits temporomandibular joint destruction in adjuvant arthritic rats. Ann N Y Acad Sci 1994, 732:427-430.
72. Leung MK, Greenwald RA, Ramamurthy NS, Moak SA, Golub LM: Tenidap and flurbiprofen enhance uptake of matrix metalloproteinase inhibitor, 4-dedimethylamino tetracycline in inflamed joints of adjuvant arthritic rats. J Rheumatol 1995, 22:1726-1731.
73. Ganu V, Doughty J, Spirito S, Goldberg R: Elevation of urinary pyridinoline in adjuvant arthritic rats and its inhibition by doxycycline. Ann N Y Acad Sci 1994, 732:416-418.
74. Yu L, Smith G, Brandt K, O'Connor B, Myers S: Therapeutic administration of doxycycline (DOXY) slows the progression of cartilage destruction in canine osteoarthritis (OA). Trans Orthop Res Soc 1993, 18:724.
75. Yu LP, Smith GN, Brandt KD, Capello WN: Preoperative oral administration of doxycycline reduces collagenase in extracts of human osteoarthritic cartilage [abstract]. Arthritis Rheum 1995, 37:S362.
76. Greenwald R, Golub L, eds.: Inhibition of Matrix Metalloproteinases: Therapeutic Potential. Ann N Y Acad Sci 1994, 732:1-507. This is the published proceedings of a 4-day conference whose discussants and attendees represented a broad array of disciplines. The conference covered the physiologic and pathologic roles of the MMPs and approaches that may be taken to suppress the pathologically excessive activity that characterizes many disease processes. The papers in this volume, including the transcription of a clinical roundtable, provide a broad viewpoint on the mechanisms, clinical indications, and plans for implementation of MMP inhibition of human disease.